• LivaNova PLC announced that Stefano Folli will join the company as incoming President of its nearly US$800 million Cardiopulmonary business on June 1, 2026, succeeding retiring leader Franco Poletti after a transition period ending July 31, 2026.
• This leadership change brings in a veteran from Philips with deep experience in global services, monitoring, and integration, potentially shaping how LivaNova manages and grows its cardiopulmonary portfolio, including the Essenz Perfusion System.
• We’ll now examine how bringing in former Philips executive Stefano Folli to run cardiopulmonary may influence LivaNova’s investment narrative.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

LivaNova Investment Narrative Recap

To own LivaNova, you need to believe in its ability to grow across cardiopulmonary and neuromodulation while defending premium pricing and margins despite healthcare cost pressure. The Folli appointment looks more like a continuity move than a near term catalyst shift, with the key upside driver still tied to execution in cardiopulmonary and OSA, and the biggest risk remaining potential pricing and reimbursement pressure across core therapies.

The recent FDA PMA approval for the aura6000 System for obstructive sleep apnea is the clearest link to the current story, because it highlights how LivaNova is trying to diversify beyond cardiopulmonary while still relying heavily on specialized, higher cost therapies. How effectively Folli shapes the Essenz Perfusion System and broader CP business will sit alongside aura6000 commercialization as investors watch for signs that growth can justify current valuation.

But against that opportunity, investors should be aware of the risk that payers push harder against premium pricing and...

LivaNova's narrative projects $1.7 billion revenue and $173.6 million earnings by 2029.

Uncover how LivaNova's forecasts yield a $79.18 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$1.6 billion and earnings US$261.5 million by 2028, so this cardiopulmonary leadership change might either support that bullish view or prompt you to question whether such upgrades, and supply chain execution in CP, are really achievable.

Explore 3 other fair value estimates on LivaNova - why the stock might be worth just $79.18!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your LivaNova research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.